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REVIEW

Tigecycline in the treatment of complicated
intra-abdominal and complicated skin and skin
structure infections
Mary L Townsend 1
Melanie W Pound 1
Richard H Drew 1,2,3
Campbell University School of
Pharmacy, Buies Creek, NC, USA;
2
Duke University Medical Center,
Durham, NC, USA; 3 Duke University
School of Medicine, Durham, NC, USA
1

Abstract: Tigecycline, a glycylcycline related to the tetracycline class of antibiotics, represents
a new option for the treatment of complicated intra-abdominal and complicated skin and skin
structure infections. It displays favorable activity in vitro against the most common causative
Gram-positive, Gram-negative and anaerobic pathogens. In addition, tigecycline demonstrates
activity against drug-resistant pathogens such as methicillin-resistant Staphylococcus aureus,
vancomycin-resistant enterococci, and organisms (such as Escherichia coli and Klebsiella
pneumoniae) producing extended-spectrum beta-lactamases. Tigecycline lacks activity in vitro
against Pseudomonas and Proteus spp. In randomized clinical trials, tigecycline administered
intravenously twice daily has demonstrated efficacy similar to comparators for a variety of
complicated skin and skin structure and complicated intra-abdominal infections. The potential
for significant drug interactions with tigecycline appears to be minimal. Dosing adjustment is
needed for patients with severe hepatic impairment. The predominant side effect associated
with its use to date has been gastrointestinal intolerance (nausea and vomiting).
Keywords: tigecycline, intra-abdominal infections, complicated skin and skin structure
infections
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Tigecycline, formerly GAR-936 (Tygacil®; Wyeth Pharmaceuticals, Inc., Philadelphia,
PA, USA), is a glycylcycline antimicrobial currently approved by the Food and
Drug Administration (FDA) for the treatment of complicated intra-abdominal
infections (cIAIs) and complicated skin and skin structure infections (cSSSIs) (Wyeth
Pharmaceuticals 2007b). In addition to its broad spectrum in vitro activity against
Gram-positives, Gram-negatives and anerobes, tigecycline demonstrates activity in
vitro against MRSA, VRE, and ESBL-producing organisms (Wyeth Pharmaceuticals
2007b). Therefore, it has potential applications in the management of polymicrobial
infections or those due to resistant organisms.
Two of the most prevalent bacterial infections in clinical practice are cSSSIs
and cIAIs. For example, surgical site infections are estimated to occur 500,000
times per year among the 27 million surgical procedures performed (CDCP 1997).
Studies evaluating the impact of surgical site infections have demonstrated that these
infections are consistently associated with an increase in healthcare costs, prolonged
hospitalizations, and an increase in morbidity and mortality (Vegas et al 1993; Kirkland
et al 1999). Specifically, one study, evaluating cSSSI following hip replacement
surgeries, found a median increased length of stay of 32.5 days directly related to the
cSSSI; additionally, the morbidity rate associated with the cSSSI was 14.3% (Monge
et al 2006). Similarly, the incidence of cIAIs is also difficult to determine because of
its inclusion of a broad range of diagnoses. Among these, complicated appendicitis
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was 8.9% from 2002–2004, with the highest rates in the
Asia/Pacific region (16.6%) (Bochicchio et al 2006).
The purpose of this article is to review the in vitro activity,
pharmacokinetics, pharmacodynamics and clinical efficacy
and safety of tigecycline for the treatment of cIAIs and cSSSIs.
Tigecycline’s role in therapy will also be discussed.

may occur in up to 30% of appendicitis cases (Cueto et al
2006). Additionally, cIaIs account for considerable hospital
cost (Solomkin, Mazuski et al 2003). Inappropriate treatment
has been associated with both treatment failures as well
as increased mortality (Solomkin, Mazuski et al 2003).
For example, Sturkenboom et al (2005) found a clinical
failure rate of 35.7% and a mortality rate of 10.7% among
patients receiving initial inappropriate therapy with
intraabdominal infections.
Effective management of both cIAIs and cSSSIs require
the timely institution of appropriate antimicrobital therapy
and, in select cases, surgical interventions (Solomkin,
Mazuski et al 2003; Stevens et al 2005). However, increases
in antibiotic resistance seen in bacteria commonly causing
such infections has made selection of appropriate empiric
therapy challenging (Bochicchio et al 2006; Moet et al 2007).
Data recently published from a worldwide multi-center
longitudinal antimicrobial resistance tracking program, the
SENTRY Antimicrobial Surveillance Program, reported
rates of methicillin-resistant Staphylococcus aureus (MRSA)
causing skin and skin structure infections ranging from 22.8%
in Europe to 35.9% in North America (Moet et al 2007).
Isolation of vancomycin-resistant enterococci (VRE) ranged
from 3.6% in Europe to 12.2% in North America. Furthermore,
Gram-negative organisms have also demonstrated diminished
susceptibility. For example, reported rates of multidrugresistant Pseudomonas aeruginosa and extended-spectrum
beta-lactamase (ESBL) producing Klebsiella spp. were 3.2%
and 11.3% in North America, and 24.7% and 48.0% in Latin
America, respectively. ESBL-producing Escherichia coli
rates ranged from 6.6% in North America to 15.1% in Latin
America (Moet et al 2007).
Rates of resistant organisms isolated in patients with
cIAIs are also increasing. In vitro susceptibilities for over
7,000 E. coli isolates from patients with intra-abdominal
infections varied according to geographic region (Bochicchio
et al 2006). The rate of ESBL-producing E. coli worldwide
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Overview of tigecycline
Pharmacology
Tigecycline (C29H39N5O8) is the first of a new class of
antimicrobials called glycylcyclines, which are related
to the tetracycline class (Wyeth Pharmaceuticals 2007b).
Although structurally similar to minocycline, it differs
primarily by the presence of a side chain addition at position 9
(Figure 1). Tigecycline possesses a similar mechanism of action
to tetracyclines in that it binds to the bacterial 30S ribosomal
subunit, thereby inhibiting bacterial protein synthesis (Bergeron
et al 1996). However, the binding affinity for tigecycline to this
ribosomal site is approximately 5 times that of tetracyclines
(Bergeron et al 1996). Tigecycline also demonstrates 70S
ribosomal subunit binding, with up to 100-fold greater affinity
as compared with tetracycline (Olson et al 2006).
Resistance to the tetracycline class most frequently
involves protection of the ribosome and/or efflux pumps
(Chopra et al 1992; Speer et al 1992; Bergeron et al 1996)
Binding to the 30S ribosomal subunit is thought to prevent
ribosomal protection (Rasmussen et al 1994; Tally et al
1995; Projan 2000; Chopra et al 2001; Zhanel et al 2004).
Efflux pumps are responsible for expelling drug from the
intracellular to extracellular space, thus preventing action
of the drug and therefore causing resistance (Li et al 1995;
Poole et al 1996; Kohler et al 1997; Aires et al 1999; Mine
et al 1999; Westbrock-Wadman et al 1999; Dean et al 2003).
In contrast to tetracyclines, tigecycline is not usually affected
by efflux pumps. However, tigecycline is susceptible to
efflux pumps of the “resistance nodulation division” (RND)
which are common among P. aeruginosa (Projan 2000);
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tigecycline is a know substrate for the pumps, described as
MexAB-OprM, MexCD-OprJ, MexEF-OprN and MexXYOprM (Dean et al 2003). While Acinetobacter baumannii is
generally sensitive to tigecycline, it can possess 2 of these
RND pumps. Therefore, although further study is needed,
emerging resistance to tigecycline while on therapy may be
a concern for this organism (Rice 2006). Tigecycline appears
to be unaffected by other mechanisms of resistance, including
enzyme target changes and target site modifications.
Production of beta-lactamases (including ESBLs) also do
not influence tigecycline’s antimicrobial activity (Wyeth
Pharmaceuticals 2007b).

Microbiology
The Clinical and Laboratory Standards Institute (CLSI) has
set the tigecycline in vitro minimum inhibitory concentration
(MIC) susceptibility breakpoints for Streptococcus spp.
(excluding S. pneumoniae) and Enterococcus faecalis
(vancomycin-susceptible organisms) at 0.25 µg/mL. MIC
breakpoints to be considered susceptible to tigecycline for
S. aureus (including both MSSA and MRSA) are 0.5 µg/mL,
while Enterobacteriaceae and anaerobes are set at 2 µg/mL
and 4 µg/mL, respectively (CLSI 2003a, 2003b, 2004, 2005;
Wyeth Pharmaceuticals 2007b). The European Committee on
Antimicrobial Susceptibility Testing (EUCAST) susceptibility
breakpoint for Enterobacteriaceae however, is 1 µg/mL,
and breakpoints have not been established for anaerobes
(EUCAST Steering Committee 2006).
Tigecycline displays excellent in vitro activity against
most Gram-positive organisms (Sader et al 2005). A recent
study evaluating 26,474 bloodstream infection isolates
from 6 different continents found 99.4% (n = 8765) of
S. aureus isolates susceptible with an MIC90 = 0.5 µg/mL
(range of 0.016–1 µg/mL) (Sader et al 2005). In this same
study, 92.7% (n = 3258) of Enterococcus spp. were considered sensitive to tigecycline, with an MIC90 of 0.25 µg/mL
(range of 0.016–2 µg/mL). Over 97 % (n = 605) of
S. pneumoniae and viridans group streptococci (n = 378) were
also considered susceptible, with MIC90 of 0.12 µg/mL
(range 0.12–1 µg/mL) and 0.12 µg/mL (range 0.12–
0.5 µg/mL), respectively (Sader et al 2005).
In general, tigecycline demonstrated activity against
Gram-positive bacteria resistant to other classes of antibiotics.
Susceptibility of S. aureus to tigecycline appears to be
independent of oxacillin susceptibility (Sader et al 2005).
In addition, a vancomycin-resistant S. aureus strain
(VRSA) isolated at Hershey Medical Center demonstrated
an MIC of 0.125 µg/mL to tigecycline (Bogdanovich et al

Therapeutics and Clinical Risk Management 2007:3(6)

2005). Tigecycline also has potent in vitro activity against
quinolone-resistant S. pneumoniae, with a reported MIC of
0.12 µg/mL (Garrison et al 2007). For vancomycin-resistant
E. faecium (n = 77) and vancomycin-resistant E. faecalis
(n = 11), the MIC90 were 0.06 µg/mL and 0.12 µg/mL,
respectively with 100% susceptibility in both species
(Hoban et al 2005).
Tigecycline has shown potent in vitro activity against
most Gram-negative organisms, with the exception of
Proteus (n = 320) and Pseudomonas spp. (n = 1,338) with
MIC90 (and ranges) of 4 µg/mL (0.25–16 µg/mL) and
32 µg/mL (0.008–32 µg/mL), respectively (Sader et al
2005). E. coli (n = 3217) and Klebsiella spp. (n = 1,503) are
also susceptible to tigecycline. The MIC90 (and ranges) of
0.25 g/mL (0.03–4 µg/mL) and 1 µg/mL (0.06–8 µg/mL)
have been reported for these organisms, respectively (Sader
et al 2005). Tigecycline also demonstrates activity against
ESBL-producing strains of these pathogens. MIC90 (range)
values for 142 ESBL-producing E. coli isolates and 278
ESBL-producing K. pneumoniae isolates were 1 µg/mL
(0.25–2 µg/mL) and 2 µg/mL (0.25–8 µg/mL), respectively
(Bouchillon et al 2005b). MICs ranging 0.03–8 µg/mL and
an MIC90 of 1 µg/mL was reported in the largest published
study of Acinetobacter spp. isolates (n = 851) to date (Waites
et al 2006). While several other in vitro studies have reported
a high percentage of Acinetobacter spp. susceptible MICs
according to CLSI criteria, many of these organisms would be
considered resistant if utilizing EUCAST criteria (Bouchillon
et al 2005a, 2005b; Sader et al 2005; Waites et al 2006).
Tigecycline also remains active against carbapenem-resistant
A. baumannii and pan-resistant A. baumannii according
to 2 recent case reports, although tigecycline-resistant
A. baumanii has emerged clinically (Bogaerts et al 2006;
Taccone et al 2006; Peleg et al 2007).
Anaerobic activity of tigecycline has been studied in
several clinical trials in which the results are summarized
in a study by Bradford et al (Bradford et al 2005). Results
from these studies demonstrate tigecycline’s potent anaerobic
activity against Clostidium perfringens, Propionibacterium
acnes, and Bacteroides fragilis. MICs for these organisms
were below the CLSI susceptibility breakpoint of 4 µg/mL
(Bradford et al 2005). Table 1 describes further the in vitro
susceptibilities of tigecycline.

Pharmacokinetics
Tigecycline exhibits linear kinetics following intravenous
(IV) administration (Muralidharan, Micalizzi et al 2005). Data
from 103 healthy adult volunteers who received tigecycline
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Table 1 In vitro susceptibilities of select aerobic and anaerobic organisms to tigecyclinea
Organism

No. of
isolates

MIC90b

MIC
rangeb

%
Susceptiblec

References

Staphylococcus aureus
MSSA
MRSA
VISA
Staphylococci, coagulasenegative (CoNS)
CoNS, methicillin
susceptible
CoNS, methicillin resistant
S. pneumoniae
S. pneumoniae, penicillin
susceptible
S. pneumoniae, penicillinresistant
Streptococci, β-hemolytic
Streptococci, viridans
group
Enterococci spp.
Enterococcus spp.vancomycin susceptible
Enterococcus spp.vancomycin resistant
Nocardia spp.
Escherichia coli
ESBL-producing E.coli
Klebsiella pneumonia
ESBL-producing
K. pneumoniae
Klebsiella oxytoca
Enterobacter aerogenes
Enterobacter cloacae
Haemophilus influenzae
H. influenzae, β-lactamase
positive
Moraxella catarrhalis
Serratia marscens
Citrobacter spp.
Acinetobacter baumannii
Pseudomonas aeruginosa
Stenotrophomonas
maltophilia
Burkholderia cepacia
Campylobacter jejuni
Campylobacter coli
Proteus mirabilis
Bacteroides fragilis
Bacteroides fragilis group
B. distasonis
B. ovatus
B. thetaiotaomicron
B. vulgatus
C. perfringens
Clostridium difficile
Fusobacterium varium
Lactobacillus spp.

8765
813
879
19
3570

0.5
0.12
0.25
0.5
0.5

0.016–1
0.015–0.5
0.03–0.5
0.06–1
0.016–2

99.4
100
100
NAd
97.5

(Sader et al 2005)
(Waites et al 2006)
(Waites et al 2006)
(Petersen et al 2002)
(Sader et al 2005)

71

0.5

0.03–1

NAd

(Fritsche, Sader et al 2005)

189
605
279

0.5
0.12
0.5

0.12–2
0.12–1
NAd

NAd
--e
NAd

(Fritsche, Sader et al 2005)
(Sader et al 2005)
(Hoban et al 2005)

54

0.25

NAd

NAd

(Hoban et al 2005)

769
378

0.12
0.12

0.12–0.5
0.12–0.05

99.7
98.1

(Sader et al 2005)
(Sader et al 2005)

3258
466

0.25
0.5

0.016–2
0.12–1

92.7
NAd

(Sader et al 2005)
(Fritsche, Sader et al 2005)

39

0.25

0.03–0.5

NAd

(Fritsche, Sader et al 2005)

51
3217
115
1334
126

4
0.25
0.38
2
2

0.06–8
0.03–4
0.047–0.75
0.008–8
0.12–8

NAd
99.9
NAd
95
92.1

(Cercenado et al 2007)
(Sader et al 2005)
(Sorlozano et al 2006)
(Waites et al 2006)
(Waites et al 2006)

248
419
1089
336
93

1
1
2
0.25
0.25

0.06–4
0.06–8
0.008–8
NAd
NAd

98.8
95.7
93
--e
--e

(Waites et al 2006)
(Waites et al 2006)
(Waites et al 2006)
(Hoban et al 2005)
(Hoban et al 2005)

54
658
252
851
1338
203

0.5
1
0.5
1
32
2

NAd
0.012–8
NAd
0.03-8
0.008–32
0.12–8

--e
97
86.9
--e
--e
--e

(Gales et al 2005)
(Waites et al 2006)
(Fritsche, Strabala et al 2005)
(Waites et al 2006)
(Waites et al 2006)
(Sader et al 2005)

21
108
8
320
2721
5225
274
545
978
306
51
12
13
15

16
4
16
4
8
8
8
8
8
4
1.0
0.06
0.25
0.5

0.25–32
0.12–16
0.5–16
0.25–16
0.06–32
0.06–64
0.25–32
0.125–16
0.25–32
0.25–16
0.06–2
0.06
0.06–0.25
0.06–1

--e
--e
--e
46.9
94.9
95.7
97.9
96.7
96.4
98.4
NAd
NAd
NAd
NAd

(Cheng et al 2005)
(Rodriguez-Avial et al 2006)
(Rodriguez-Avial et al 2006)
(Sader et al 2005)
(Snydman et al 2007)
(Snydman et al 2007)
(Snydman et al 2007)
(Snydman et al 2007)
(Snydman et al 2007)
(Snydman et al 2007)
(Bradford et al 2005)
(Goldstein et al 2006)
(Goldstein et al 2006)
(Goldstein et al 2006)

Adapted with permission from (Townsend ML et al 2006. Tigecycline: a new glycylcycline antimicrobial. Int J Clin Pract, 60:1662–72. Blackwell Publishing.) bMIC = minimum
inhibitory concentration. cAccording to CLSI criteria. dNA= not available. eNo CLSI criteria available.

a
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intravenously (100 mg followed by 50 mg every 12 hours over
60 minutes) produced steady state maximum plasma concentrations (Cmax) and minimum plasma concentrations (Cmin) of
0.63 µg/mL and 0.13 µg/mL, respectively. The area under the
plasma concentration-time curve from 0 to 24 hours (AUC0–24)
was 4.70 µg·h/mL (Muralidharan, Micalizzi, et al 2005; Wyeth
Pharmaceuticals 2007b). Patients with cSSSIs (n = 81) participating in a phase II study demonstrated pharmacokinetic parameters similar to healthy adult volunteers, with a Cmax of 0.403
µg/ml and AUC0–12 of 2.24 µg·h/mL (Postier et al 2004).
Tigecycline is highly protein bound (71%–89%) at
plasma drug concentrations achieved in clinical trials
(0.1–1.0 µg/mL) (Wyeth Pharmaceuticals 2007b). The
volume of distribution of tigecycline reported from healthy
volunteer studies is 7–10 L/kg (Muralidharan, Micalizzi et al
2005). Based on animal and human studies, tigecycline can
distribute into various bodily fluids and tissues, such as the
lungs, skin, peritoneal fluid, gall bladder, colon, heart, liver,
meninges and bone (Tombs 1999; Rodvold et al 2005; Conte
et al 2005; Gotfried et al 2005; Sun et al 2005; Rodvold et al
2006; Scheetz et al 2006; Wyeth Pharmaceuticals 2007b). In
adults undergoing medical or surgical procedures (n = 104),
serum, tissue, and body fluid concentrations of tigecycline
were evaluated following a single dose of 100 mg of
tigecycline administered over 30 minutes (Rodvold et al
2006). The mean ratio of tigecycline in the tissue to serum
(expressed as AUC0–24) was 537 in the bile, 23 for the gall
bladder, 2.6 for the colon, and 2.0 for the lung (Rodvold
et al 2006). The highest concentration of tigecycline was
found in the bile, which is consistent with the drug’s known
route of elimination. Additionally, lower tissue to serum
concentrations were achieved in the bone, synovial fluid, and
cerebrospinal fluid (CSF). The mean ratio of tigecycline in the
tissue to serum (expressed as AUC0–24) was 0.41 for the bone,
0.31 for the synovial fluid, and 0.11 for the CSF. The highest
CSF to serum ratios occurred approximately 24 hours after
infusion. Of note, bone penetration of tigecycline in animal
models was higher than what was achieved in this human
study (Tombs 1999; Rodvold et al 2006). The inconsistency
of bone penetration in this study versus previous animal
studies may have been due to poor extraction techniques,
tight binding of the drug to bone, or the single dose design
of the study. Additionally, peritoneal fluid penetration of
tigecycline has been reported in a critically ill patient. The
extrapolated penetration into the peritoneal fluid was about
50% (Scheetz et al 2006). Tigecycline has also been shown
to have a 74% (mean) penetration into cantharidin-induced
blisters in healthy volunteers (n = 10) (Sun et al 2005).

Therapeutics and Clinical Risk Management 2007:3(6)

Tigecycline is not extensively metabolized. The main
metabolic pathway of tigecycline is glucuronidation. Nonactive metabolites that were recovered in the urine and feces
include a glucuronide, its epimer (M1 and M2), and N-acetyl9-aminominocycline (M6) (Hoffmann et al 2004; Rello 2005;
Wyeth Pharmaceuticals 2007b). The pharmacokinetic model
of tigecycline follows a 2-compartment model with firstorder elimination based on pooled data from Phase II and III
studies involving patients with cSSSIs and cIAIs (Van Wart
et al 2006). The primary route of elimination of tigecycline
is through feces and the biliary tract (59%) as unchanged
drug and metabolites. Secondary routes of elimination
include glucuronidation and renal excretion (33%). Renal
excretion only accounts for about 10%–15% of the systemic
clearance of tigecycline (Hoffmann et al 2004; Muralidharan,
Micalizzi et al 2005). The terminal half-life of tigecycline
is 37–67 hours and the total systemic clearance is 0.2–0.3
L/h/kg (Muralidharan, Micalizzi et al 2005).

Pharmacodynamics
Tigecycline demonstrates time-dependent bacteriostatic
activity in vitro (van Ogtrop et al 2000; Reese et al 2005). Its
post-antibiotic effect against Gram-negative organisms ranges
from 2 to 5 hours, and 8.9 hours for S. pneumoniae (van Ogtrop
et al 2000; Reese et al 2005). Recent animal and clinical data
suggests the area-under-the concentration-time curve (AUC)
to MIC ratio (AUC/MIC) may be a reliable predictor for
efficacy with tigecycline (Meagher et al 2005; Garrison et al
2007; Meagher et al 2007). The AUC/MIC ratios described
in the literature for in vitro activity range from 79–158
when evaluating quinolone-resistant S. pneumoniae, MRSA
and VRE (Garrison et al 2007). In a study by Meagher and
colleagues (Meagher et al 2007), cSSSI patients with S.aureus
and streptococci as the primary organisms were evaluated to
determine the pharmacodynamic properties of tigecycline.
Based on the results of this study, the AUC/MIC ratio of 17.9
or higher was a significant predictor of both microbiological
and clinical response in cSSSI patients (Meagher et al
2007). Although the AUC/MIC ratios range in the literature
depending on the organism and infection, no consensus to date
has been reached to determine the ideal AUC/MIC ratio for
particular disease states.

Special populations
Tigecycline’s pharmacokinetic profile appears to be independent of age, ethnic backgrounds (African-American,
Hispanic, Asian, and Caucasian), and gender. (Meagher
et al 2005; Muralidharan, Fruncillo et al 2005). Patients with
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renal impairment (creatinine clearance of 30 mL/min or
hemodialysis-dependent) had a non-significant increase in
Cmax and AUC in comparison to healthy volunteers (Troy
et al 2003). Additionally, tigecycline was not found to be
significantly removed via hemodialysis. Therefore, no dosing
adjustments are necessary in patients with renal dysfunction
or who are hemodialysis dependent (Troy et al 2003; Wyeth
Pharmaceuticals 2007b). In contrast to patients with renal dysfunction, patients with severe hepatic impairment (ie, ChildPugh Class C) had a 43% increase in tigecycline’s half-life and
a 55% reduction in drug clearance (Saunders et al 2005). Thus,
it is recommended in these patients that the maintenance dose
of tigecycline be reduced to 25 mg every 12 hours in patients
with severe hepatic insufficiency (Wyeth Pharmaceuticals
2007b). No adjustments are needed for patients with mild
to moderate hepatic impairment (Child-Pugh Class A or B)
(Wyeth Pharmaceuticals 2007b). Pharmacokinetic studies
are currently lacking in obese/low-body-weight individuals,
the pediatric population, and patients who are lactating
or pregnant.

Drug interactions
To date, no significant drug-drug interactions have been
reported with tigecycline. Tigecycline is not metabolized
by the cytochrome P450 system and as a result, it does not
alter the metabolism of drugs that go through this system
nor do these drugs affect the concentration of tigecycline
(Wyeth Pharmaceuticals 2007b). Studies evaluating the
concurrent administration of tigecycline with either digoxin
or warfarin in healthy adults have not demonstrated a
significant drug-drug interaction between tigecycline and
either of these drugs (Zimmerman et al 2004; Raible et al
2005; Wyeth Pharmaceuticals 2007b; Zimmerman et al
2007). However, the manufacturer of tigecycline does
recommend that the international normalized ratio (INR)
as well as signs and symptoms of bleeding be routinely
assessed when tigecycline is administered with warfarin
(Wyeth Pharmaceuticals 2007b).

Safety and tolerability
Overall, tigecycline was well-tolerated in phase III clinical
studies with only 5% of patients discontinuing therapy due
to adverse events in comparison to 4.7% in the comparator
arms (vancomycin-aztreonam 5.3% and imipenem-cilastatin
4.4%) (Babinchak et al 2005; Ellis-Grosse, Babinchak et al
2005; Wyeth Pharmaceuticals 2007b).
The most common adverse events associated with the
administration of tigecycline in phase II and III studies was
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mild to moderate nausea and vomiting. This occurred most
often during the first 2 days of drug therapy, and was the most
common reason for discontinuing drug therapy (Postier et al
2004; Oliva et al 2005; Babinchak et al 2005; Breedt et al
2005; Fomin et al 2005; Muralidharan, Fruncillo et al 2005;
Muralidharan, Micalizzi et al 2005; Sacchidanand et al 2005;
Wyeth Pharmaceuticals 2007b). The incidence of nausea was
34.5% (versus 8.2% in vancomycin-aztreonam; p  0.001)
in the cSSSIs studies and 24.4% (versus 19% in imipenemcilastatin; p = 0.01) in the cIAIs studies. The incidence of
vomiting was 19.6% (versus 3.6% in vancomycin-aztreonam;
p  0.001) and 19.2% (versus 14.3% in imipenem-cilastatin;
p = 0.008) in cSSSIs and cIAIs studies, respectively (Oliva
et al 2005; Babinchak et al 2005; Fomin et al 2005; Breedt
et al 2005; Ellis-Grosse, Babinchak et al 2005). The exact
mechanism of tigecycline-induced nausea and vomiting
remains unknown, but it is not related to the release of serotonin in the gastrointestinal tract (Muralidharan, Micalizzi et al
2005). Nausea and vomiting has occurred more frequently at
higher doses and in patients 50 years of age, female, and
non-European descent (Muralidharan, Fruncillo et al 2005;
Wyeth Pharmaceuticals 2007b). While coadministration of
food may potentially improve the tolerability of tigecycline,
altering the rate of infusion has not been successful in deceasing the incidence of nausea and vomiting (Muralidharan,
Micalizzi et al 2005). Likewise, administration of antiemetics
(such as prochlorperazine, ondansetron, or metoclopramide)
does not significantly alter the incidence of nausea and vomiting (Muralidharan, Micalizzi et al 2005; Wyeth Pharmaceuticals 2007b). During phase III clinical studies, diarrhea was
reported in 12.7% of patients receiving tigecycline (Wyeth
Pharmaceuticals 2007b). However, there were no published
cases of Clostridium difﬁcile associated diarrhea in these clinical studies (Babinchak et al 2005; Ellis-Grosse, Babinchak
et al 2005; Wyeth Pharmaceuticals 2007b).
Tigecycline’s ability to induce C. difﬁcile infections has
also been evaluated (Baines et al 2006). In a human gut model
involving 2 epidemic strains of C. difﬁcile, the gut flora was
significantly decreased although the C. difﬁcile spores did
not “proliferate”; in addition, cytotoxin was not produced
(Baines et al 2006). This seems to correlate clinically, as only
limited cases of C. difﬁcile infections have been reported with
tigecycline to date (Wyeth Pharmaceuticals 2007a). However,
as with all antimicrobials, tigecycline can theoretically
predispose a patient to a C. difﬁcile infection.
Due to the structural similarities between tetracyclines
and tigecycline, cross-reactivity may occur between these two
classes of drugs, and caution should be used in patients with
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known hypersensitivity reactions to tetracyclines (Zhanel
et al 2004; Wyeth Pharmaceuticals 2007b). Furthermore,
similar side effects may exist between tetracyclines and
tigecycline such as photosensitivity reactions, pancreatitis,
and tooth discoloration in children under 8 years old (Zhanel
et al 2004; Wyeth Pharmaceuticals 2007b). Long-term safety
has not been published with the use of tigecycline to date.

Clinical efficacy
Complicated intra-abdominal infections
As with any type of infection, the objectives for the treatment
of cIAI are to minimize the time to clinical improvement, prevent recurrence, and eradicate the causative microorganisms.
As with most infections, healthcare-associated infectious
diseases generally require broader antibacterial coverage for
such resistant organisms as P. aerunginosa, Enterobacter
spp. and MRSA as compared with community-associated
infections (Solomkin, Mazuski et al 2003).
Guidelines published by the Infectious Diseases Society
of America for the treatment of cIAIs describe the use of a
single-agent, broad-spectrum antimicrobial agent or the use
of a combination of antibiotics with activity against common
enteric flora (Solomkin, Mazuski et al 2003). They summarize
data from numerous trials. For example, monotherapy for
the treatment of cIAIs studied in randomized, prospective
clinical trials include the β-lactam/β-lactamase inhibitors
such as ampicillin/sulbactam, piperacillin/tazobactam, and
ticarcillin/clavulanic acid (Eklund et al 1993; Walker et al
1993; Dougherty et al 1995; Jaccard et al 1998; Allo et al
1999; Ohlin et al 1999; Cohn et al 2000). The carbapenems
(ertapenem, imipenem/cilastatin and meropenem) as well as
certain cephalosporins (ceftotetan and cefoxitin) have also
been studied (Poenaru et al 1990; Brismar et al 1992; Eklund
et al 1993; Brismar et al 1995; Condon et al 1995; Geroulanos
1995; Huizinga et al 1995; Angeras et al 1996; Berne et al
1996; Christou et al 1996; Colardyn et al 1996; Solomkin
et al 1996; Barie et al 1997; Basoli et al 1997; Donahue
et al 1998; Allo et al 1999; Solomkin et al 2001; Solomkin,
Mazuski et al 2003; Solomkin, Yellin et al 2003). As for combination regimens, aminoglycosides, quinolones or certain
cephalosporin agents in addition to anti-anaerobic medications
(clindamycin or metronidazole) also have data to support their
use (Solomkin, Mazuski et al 2003).
Tigecycline has been studied specifically in adult patients
with cIAIs in 2 phase III, noninferiority, multicenter,
randomized, double-blind trials (Oliva et al 2005; Fomin
et al 2005) and are presented together in a pooled analysis
(Babinchak et al 2005). Patients 18 years old and older who
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also required surgical intervention for treatment of cIAIs were
included. The cIAIs were defined as perforated intestines,
intra-abdominal abscesses, appendicitis, diverticulitis, or
cholecysitis with perforation and/or abscess with fecal
contamination, or perforated gastric/duodenal ulcers, and
complicated peritonitis (Babinchak et al 2005). Patients were
stratified by randomization according to their APACHE II
scores and received either intravenous tigecycline 100 mg
followed by 50 mg every 12 hours or intravenous imipenemcilastatin 500 mg every 6 hours (adjusted based on the
patient’s weight and renal function). Patients were generally
treated for 5–14 days.
The primary endpoint for these studies was “the clinical
response at the test-of-cure visit (12–42 days after therapy)
in the co-primary end point microbiologically evaluable
[ME] and microbiological modified intent-to-treat [mm-ITT]
populations” (Babinchak et al 2005).
A total of 1658 patients were randomized in these
2 trials; the mm-ITT population included 1262 patients,
and the ME population was composed of 1025 patients. The
mean of subject age was 47 years, and the most commonly
reported intra-abdominal infection was complicated appendicitis (50.6%, tigecycline and 48.7%, imipenem-cilastatin)
followed by complicated cholecystitis (12.8%, tigecycline
and 15.1%, imipenem-cilastatin). The average APACHE
II score was 6.3 (tigecycline group) and 6 (imipenemcilastatin) with only 35 patients having an APACHE II score
15. The mean duration of therapy with either agent was
approximately 8 days (Babinchak et al 2005). Clinical cures
were reported in 80.2% (506/631) and 81.5% (514/631) of
tigecycline and imipenem m-mITT groups, respectively
(% difference (95%CI): −1.3% (–5.8% to 3.2%)). The ME
population had similar response rates, with 86.1% (441/512)
and 86.2% (442/513) clinical cure rate in the tigecycline and
imipenem-cilastatin groups, respectively (Babinchak et al
2005). Although many organisms were identified, the most
commonly isolated organisms included E. coli (n = 665),
S. anginosus (n = 198), K. pneumonia (n = 112) and B. fragilis
(n = 160) (Babinchak et al 2005). The most commonly
reported adverse events reported in these studies included
gastrointestinal complaints with a statistically higher rate in
the tigecycline group compared with those receiving imipenem-cilastatin. There were a total of 44.4% and 39.4%
of reported adverse events with the digestive system in the
tigecycline and imipenem-cilastatin patients, respectively
(p = 0.04) (Babinchak et al 2005).
Based on the results of this analysis, tigecycline appears to
be as safe and effective as imipenem in cIAIs. One limitation
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in this trial was the relatively few resistant organisms isolated.
Thus, these studies may not apply to the patient population
in which resistance is a concern. Additional clinical trials
examining tigecycline’s use in cIAIs including resistant
organisms will further the utility of tigecycline in this type
of infection.

Complicated skin and skin structure
infections
Complicated skin and skin structure infections (cSSSIs) either
involve deep soft tissues or require surgical debridement
or interventions. These infections often require parenteral
antimicrobial treatment and frequently occur in patients with
other comorbid disease states (such as diabetes or peripheral
vascular disease) in which their response to antimicrobial
treatment can be suboptimal. Examples of cSSSIs include
major abscesses, burns, surgical site infections, diabetic
foot, and infected ulcers (CDER 1998; Nichols 1999, 2001;
Dinubile et al 2004; Lee et al 2005).
Numerous pathogens have been associated with cSSSIs
and are often dependent upon the patient and clinical scenario. In general though, S. aureus and Streptococcus spp.
tend to be the predominant pathogens with Gram-negatives,
anaerobes, and resistant pathogens such as MRSA becoming
more of a factor in immunocompromised patients, injection
drug users, and nosocomially-acquired infections (Rennie
et al 2003; Dinubile et al 2004). Additionally, some infections (such as lower extremity infections in diabetic patients)
tend to be more polymicrobial in nature (Doern et al 1999;
Rennie et al 2003; Dinubile et al 2004).
Besides surgical debridement, there are multiple antimicrobial options that are available for the treatment of cSSSIs.
Empiric antimicrobial therapy should include coverage for
Gram-positive cocci such as staphlococci and streptococci.
Additional coverage for Gram-negative organisms, anaerobes (such as B. fragilis group), or resistant pathogens is
dependent upon patient risk factors for such organisms
(Nichols 1999; Dinubile et al 2004; Stevens et al 2005; Lee
et al 2005). Local resistance patterns should also play an
important role in deciding appropriate empiric treatment.
According to the skin and soft tissue infections guidelines
set forth by the Infectious Diseases Society of America (Fass
et al 1985; Tan et al 1993; Talan et al 2000; Grayson et al
2002; Graham, Lucasti et al 2002; Graham, Talan et al 2002;
Stevens et al 2005; Fabian et al 2005; Giordano et al 2005),
treatment options include broad-spectrum antibiotics such
as carbapenems (eg, imipenem/cilastin, meropenem, ertapenem), beta-lactam/beta-lactamase inhibitor combinations
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(eg, piperacillin-tazobactam, ticarcillin-clavulanate,
ampicillin-sulbactam), cephalosporins (eg, cefazolin, cefoxitin), and fluoroquinolones (eg, levofloxacin, moxifloxacin)
used alone or in combination with clindamycin or metronidazole for anerobic coverage. The addition of vancomycin or
other newer antimicrobial agents (eg, daptomycin, linezolid,
quinupristin/dalfopristin, tigecycline) with activity against
resistant organisms such as MRSA, VRE, and ESBLproducing gram negative organisms is dependent upon the
clinical circumstances of the patient (Nichols et al 1999;
Stevens et al 2000; Stevens et al 2005; Lipsky et al 2005).
Tigecycline has been evaluated for the treatment of cSSSIs
in two randomized, multi-centered, double-blind phase 3
studies (Breedt et al 2005; Ellis-Grosse, Babinchak et al 2005;
Sacchidanand et al 2005). In both studies, hospitalized adult
patients with cSSSIs (defined as deep soft tissue infections,
soft tissue infections requiring surgical debridement, or soft
tissue infections in patients with underlying disease such as
diabetes or peripheral vascular disease) were randomized (1:1)
to receive either tigecycline (100 mg loading dose followed
by 50 mg every 12 hours over 60 minutes) or vancomycin
(1 g every 12 hours over 60 minutes with adjustments based
on renal function) plus aztreonam (2 g every 12 hours over
60 minutes) intravenously for up to 14 days. At the discretion
of the investigators, aztreonam therapy could be discontinued
after 48 hours of treatment. The clinical response at the testof-cure-visit (12–92 days after the last dose) in the clinically
evaluable (CE) and the clinical modified intention-to-treat
(c-mITT) was the primary endpoint of these studies (EllisGrosse, Babinchak et al 2005).
Pooled analysis of the data (N = 1129) demonstrated that
baseline demographics between each group was similar in
terms of type of infection and incidence of other comorbid
disease states (Ellis-Grosse, Babinchak et al 2005). Caucasian (68.2%) men (62.1%) with a mean age of 48 made up
the majority of the patients enrolled in the studies. Patients
were on antibiotic treatment for a mean of 8 days in each
group. The most common type of cSSSIs was cellulitis
(59%). In the c-mITT analysis (comprised of patients who
received at least 1 dose of the study drug and had clinical
evidence of a cSSSI; ) (N = 1057), 79.7% in the tigecycline
arm (429/538) versus 81.9% in the vancomycin-aztreonam
arm (425/519) [95% CI for the difference –2.1 (–7.1% to
2.8%)] had a clinical cure, defined as resolution of the signs
and symptoms of cSSSI and completion of antibiotic therapy.
Clinical cure rates for the CE population (defined as c-mITT
population without P. aeruginosa as sole isolate, no other
concurrent antibiotic therapy, and assessed for failure or cure
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at the TOC visit) (N = 833) were 86.5% for patients receiving
tigecycline (365/422) versus 88.6% in the comparator arm
(364/411) [95% CI for the difference, –2.1 (–6.8 to 2.7)]. The
most common organism isolated was MSSA (N = 254). Cure
rates for MSSA were 88.8% (N = 119/134) versus 90.8%
(N = 109/120), respectively for tigecycline and vancomycinaztreonam arms. Sixty-five patients had MRSA isolates, of
which 32% (N = 21/65) were considered to be communityacquired strains. Overall cure rates for MRSA were 78.1%
(N = 25/32) in the tigecycline arm and 75.8% (N = 25/33)
for the vancomycin-aztreonam arm (Ellis-Grosse, Babinchak
et al 2005). ESBL-producing organisms treated with tigecycline had clinical cure rates of 77.8% (N = 9) for E. coli,
85.7% (N = 7) for K. pneumoniae, and 100% (N = 3) for
P. mirabilis (Ellis-Grosse, Bradford et al 2005). The authors
concluded from these pooled analysis, that tigecycline was
noninferior to the combination of vancomycin-aztreonam
in the treatment of cSSSIs. The incident of adverse events
was similar between the groups (67.7% tigecycline versus
61.1% vancomycin-aztreonam) with the most common
adverse events being related to gastrointestinal complaints
(46% tigecycline versus 21% vancomycin-aztreonam; p 
0.001) (Ellis-Grosse, Babinchak et al 2005).

Conclusions
Tigecycline represents a new treatment option for both
cSSSIs and cIAIs due, in part, to its favorable in vitro
activity against a wide variety of aerobic Gram-positive,
Gram-negative and anaerobic organisms (including
multidrug-resistant pathogens such as MRSA, VRE,
and ESBL-producing strains of E. coli and Klebsiella).
In contrast, tigecycline lacks activity in vitro against
P. aeruginosa and P. mirabilis. Following twice daily
intravenous administration, it is extensively distributed
to various body tissues and fluids. Dose modification is
required in patients with significant hepatic impairment.
Because of the metabolic profile of tigecycline, the potential
for drug interactions appears to be minimal.
Based on existing clinical efficacy and safety data, tigecycline has been FDA-approved for use as monotherapy
for the treatment of cSSSIs and cIAIs. Published clinical
efficacy data in humans reports tigecycline as noninferior
to comparators for such indications. Tigecycline might be
particularly useful in suspected or documented polymicrobial infections, including those patients otherwise requiring
combination therapies due to the presence of drug-resistant
pathogens such as MRSA, VRE, or ESBL-producing strains
of E. coli and K. pneumoniae. In contrast, its role as part of
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combination therapy with other antimicrobials is uncertain.
Gastrointestinal side effects (mainly nausea) may be problematic in some patients.
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